Kabir, Ashraf Ul https://orcid.org/0000-0002-9449-8238
Zeng, Carisa https://orcid.org/0000-0002-7108-3873
Subramanian, Madhav https://orcid.org/0000-0002-1957-4982
Wu, Jun
Kim, Minseo
Krchma, Karen
Wang, Xiaoli
Halabi, Carmen M. https://orcid.org/0000-0003-4889-8131
Pan, Hua
Wickline, Samuel A.
Fremont, Daved H. https://orcid.org/0000-0002-8544-2689
Artyomov, Maxim N. https://orcid.org/0000-0002-1133-4212
Choi, Kyunghee https://orcid.org/0000-0002-9634-9375
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL149954)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL55337)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA271714)
Article History
Received: 11 March 2023
Accepted: 16 July 2024
First Online: 12 August 2024
Competing interests
: S.A.W. and H.P. have equity with Altamira Therapeutics. The other authors declare no competing interests.